SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Sun Pharma to seek shareholders approval for $4 billion acquisition of Ranbaxy

31 Jul 2014 Evaluate

Sun Pharmaceutical Industries will be seeking shareholders approval for its $4 billion acquisition of Ranbaxy Laboratories in a court convened meeting at Vadodara on August 22, 2014. The Gujarat High Court had issued an order on July 16, directing the company to hold a meeting of its equity shareholders to consider and approve the scheme of arrangement between Sun Pharma and Ranbaxy.

In April this year in one of the biggest deals involving two Indian drug makers, Sun Pharmaceutical Industries had announced it would fully acquire rival Ranbaxy Laboratories in an all-stock transaction valued at $3.2 billion along with nearly $800 million debt of the Gurgaon based firm. The combined entity would become the largest pharmaceutical company in India post the acquisition, with estimated combined revenue of $4.2 billion, and the fifth-largest specialty generics company in the world.

Recently, the two leading stock exchanges -- BSE and NSE -- gave clearance to $4-billion merger of Ranbaxy Laboratories with Sun Pharmaceutical Industries.

Sun Pharmaceutical Industries is an international, integrated, specialty pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India, US and several other markets across the world.

Sun Pharma Inds. Share Price

1675.20 -17.95 (-1.06%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×